Steve Couldwell, the chief executive of regenerative medicines specialist Tissue Regenix Group PLC (LON:TRX), is taking a temporary leave of absence early next year in order to undergo medical treatment.
Couldwell will temporarily step aside in January and is expected to be out of action until March.
In his absence, chairman John Samuel will become executive chairman, while chief financial officer Gareth Jones will take on the role of chief operating officer.
Samuel and Jones will hold those positions on an interim basis.
“Steve has done an excellent job of establishing a sound business strategy and delivering positive sales momentum,” said chairman Samuel.
“We are confident we will continue to execute against this strategy and on behalf of the Board and everyone at Tissue Regenix, I wish Steve a full and speedy recovery.”
As for current trading, a brief line at the end of the stock exchange announcement confirmed that the company remains on track to meet full-year expectations.